Alembic Pharmaceuticals shares hit a new 52-week high in morning trade after the company successfully completed a USFDA inspection of its Oncology Formulation Facility (F-2) in Panelav with no Form 483 observations. The inspection took place from October 7 to October 8, 2024.
Alembic Pharmaceuticals’ stock opened at 1,257.95 and surged to a day high of 1,303.90, setting a new 52-week high. The stock hit a day low of 1,257.00, reflecting a steady performance.
As of 10:11 am, Alembic Pharmaceuticals shares were trading 3.76 higher at Rs 1,293.70 on the NSE.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
